MTOR and neoplasm: In a study assessing the prevalence of clinically relevant genomic alterations, defined as those associated with therapeutics in either clinical trials or already approved for routine use, Gay et al. revealed that roughly half of their tumour cohort harboured such genomic alterations with particular frequency in the PI3K/mTOR signalling pathway, as well as CDK-dependent cell cycle regulation [17].